H Lundbeck A/S (CO:HLUN-A) — Market Cap & Net Worth
Market Cap & Net Worth: H Lundbeck A/S (HLUN-A)
H Lundbeck A/S (CO:HLUN-A) has a market capitalization of $1.14 Billion (Dkr7.27 Billion) as of June 15, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #8473 globally and #44 in its home market, demonstrating a -1.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying H Lundbeck A/S's stock price Dkr36.55 by its total outstanding shares 199020757 (199.02 Million). Review H Lundbeck A/S balance sheet liabilities to assess the company's total debt and financial obligations.
H Lundbeck A/S Market Cap History: 2022 to 2026
H Lundbeck A/S's market capitalization history from 2022 to 2026. Data shows growth from $710.34 Million to $1.14 Billion (4.91% CAGR).
H Lundbeck A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how H Lundbeck A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
H Lundbeck A/S's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.35x
H Lundbeck A/S's market cap is 0.35 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $710.34 Million | $18.25 Billion | $1.92 Billion | 0.04x | 0.37x |
| 2023 | $871.92 Million | $19.91 Billion | $2.29 Billion | 0.04x | 0.38x |
| 2024 | $1.04 Billion | $22.00 Billion | $3.14 Billion | 0.05x | 0.33x |
| 2025 | $1.13 Billion | $24.35 Billion | $3.19 Billion | 0.05x | 0.35x |
Competitor Companies of HLUN-A by Market Capitalization
Companies near H Lundbeck A/S in the global market cap rankings as of June 15, 2026.
Key companies related to H Lundbeck A/S by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #553 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #598 globally with a market cap of $45.26 Billion USD ( CN¥309.32 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #553 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.31 |
| #598 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.26 Billion | CN¥48.49 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
H Lundbeck A/S Historical Marketcap From 2022 to 2026
Between 2022 and today, H Lundbeck A/S's market cap moved from $710.34 Million to $ 1.14 Billion, with a yearly change of 4.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr1.14 Billion | +0.97% |
| 2025 | Dkr1.13 Billion | +8.38% |
| 2024 | Dkr1.04 Billion | +19.28% |
| 2023 | Dkr871.92 Million | +22.75% |
| 2022 | Dkr710.34 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of H Lundbeck A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more